Short Interest in Delcath Systems, Inc. (NASDAQ:DCTH) Declines By 23.0%

Delcath Systems, Inc. (NASDAQ:DCTH) was the target of a significant decline in short interest in the month of January. As of January 15th, there was short interest totalling 1,040,000 shares, a decline of 23.0% from the December 31st total of 1,350,000 shares. Based on an average daily trading volume, of 386,900 shares, the short-interest ratio is currently 2.7 days.

Delcath Systems Trading Down 2.3 %

Shares of Delcath Systems stock opened at $15.60 on Friday. Delcath Systems has a 52 week low of $3.70 and a 52 week high of $16.44. The stock has a market cap of $498.73 million, a PE ratio of -11.56 and a beta of 0.87. The company’s 50-day moving average price is $12.66 and its two-hundred day moving average price is $10.44.

Analyst Ratings Changes

Several analysts recently commented on the company. StockNews.com upgraded Delcath Systems from a “sell” rating to a “hold” rating in a research report on Friday, October 25th. Craig Hallum lifted their price objective on shares of Delcath Systems from $18.00 to $21.00 and gave the company a “buy” rating in a research note on Friday, January 17th. Canaccord Genuity Group reiterated a “buy” rating and issued a $21.00 target price on shares of Delcath Systems in a research report on Friday, October 18th. HC Wainwright restated a “buy” rating and set a $22.00 price target on shares of Delcath Systems in a research report on Tuesday, January 14th. Finally, Stephens reiterated a “buy” rating on shares of Delcath Systems in a report on Friday, October 18th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, Delcath Systems currently has a consensus rating of “Moderate Buy” and an average target price of $22.25.

Hedge Funds Weigh In On Delcath Systems

Hedge funds have recently made changes to their positions in the business. Polar Asset Management Partners Inc. bought a new stake in Delcath Systems during the third quarter worth approximately $1,594,000. Principal Financial Group Inc. bought a new stake in shares of Delcath Systems during the 3rd quarter worth $808,000. Renaissance Technologies LLC acquired a new position in shares of Delcath Systems in the 2nd quarter worth $694,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Delcath Systems during the second quarter worth $370,000. Finally, Virtu Financial LLC purchased a new stake in shares of Delcath Systems during the third quarter valued at $289,000. Institutional investors and hedge funds own 61.12% of the company’s stock.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.